Septerna Q2 revenue beats analyst estimates, driven by Novo Nordisk partnership

Septerna

10/08/2026 21:08

Overview
US biotechnology firm's Q2 revenue rose and beat analyst expectations
Net loss for Q2 narrowed compared to prior year, reflecting higher collaboration revenue
Company ended Q2 with $516.5 mln cash, expects runway at least into 2029

Outlook
Septerna expects to report SEP-479 Phase 1 SAD/MAD data in Q1 2027
Company anticipates cash position will fund operations at least into 2029
Company is evaluating development strategies for SEP-631 in mast cell-driven diseases

Result Drivers
COLLABORATION REVENUE - Q2 revenue increase driven by Novo Nordisk partnership, including amortization of upfront payment, milestone achievement, and research services
R&D SPENDING - Higher research and development expenses reflect ongoing investment in clinical pipeline

Company press release: ID:nGNX6gtPPd

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$26.75 mln
$17.88 mln (8 Analysts)
Q2 Net Loss
 
$13.03 mln
 
Q2 Loss From Operations
 
$16.84 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Septerna, Inc. is $44.00, about 13.3% above its August 7 closing price of $38.83

Reuters Recommended Reads
Aug 10 - Quanterix Q2 revenue rises 34% but cuts 2026 outlook
Aug 10 - Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook
Aug 10 - Cogent Biosciences Q2 net loss widens on higher expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)